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ABSTRACT
Objective: The purpose of this study was to determine the utility of serum CA125 determinations in
diagnosing acute salpingitis.
Methods: CA125 levels were determined for 34 women with the clinical diagnosis of pelvic
inflammatory disease (PID). Acute salpingitis was confirmed laparoscopically in 28 women
(82.3%).
Results: Twenty patients (71.4%) with laparoscopically confirmed acute salpingitis had CA125
levels greater than 7.5 units, compared with no patients (0/6) with laparoscopically normal tubes (P
0.002). The degree of elevation ofCA125 levels correlated with the severity of tubal inflammation
noted at laparoscopy. All patients with levels above 16 units had laparoscopically severe salpingitis.
Conclusions: We conclude that while CA125 levels above 7.5 units may modestly improve the
ability of the clinical diagnosis of PID to accurately reflect visually confirmed acute salpingitis,
limitations of the test make its clinical utility questionable. Infect. Dis. Obstet. Gynecol. 6:182-185,
1998. (C) 1998 Wiley-Liss, Inc.
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he glycoprotein CA125, a cell surface antigen
recognized by the OC-125 murine monoclonal
antibody, has become widely used clinically in gy-
necologic oncology. Bast first introduced its use as
a marker for ovarian cancer in 1983.1 Since that
time, it has become apparent that CA125 is not
100% specific for epithelial ovarian carcinoma.
Other gynecologic and nongynecologic cancers, en-
dometriosis, pregnancy, uterine myomas, and pel-
vic inflammatory disease (PID) have all been found
to be associated with an elevated level of CA125. z
PID continues to pose a diagnostic dilemma for
gynecologists. Clinical criteria alone do not bear a
relationship to the severity of salpingitis as graded
laparoscopically.3,4 In addition, it is now recognized
that the clinical symptoms and signs of PID are
varied, and some women may actually have "silent
salpingitis." Because of the long-term sequelae of
this disease (infertility, ectopic pregnancy, chronic
pain, pelvic abscesses, and sexual dysfunction),
prompt diagnosis and appropriate treatment are im-
perative. A laboratory marker for tubal inflamma-
tion would be of great benefit clinically in helping
to diagnose and therefore prompt treatment of this
disease.
The CA125 antigen is found in the normal adult
fallopian tube epithelium, raising the possibility
that it may be a useful marker for the clinical di-
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agnosis of salpingitis. Previous investigations look-
ing at the usefulness of CA125 determinations as a
screening test for ovarian cancer have noted that
CA125 levels may be elevated in women with PID.
CA125 levels have been studied specifically as a
tool for their predictive value in diagnosing PID
and detecting the degree of inflammation when
PID is suspected,s-7 None of these studies have
been performed on a U.S. population of patients.
The purpose of this study was to evaluate the
ability of a serum CA125 level to confirm the pres-
ence of laparoscopically visualized salpingitis and
to correlate CA125 levels with the severity of lap-
aroscopic findings in patients from an inner city
emergency room population with the clinical diag-
nosis of PID.
MATERIALS AND METHODS
The study population consisted of 34 pat[ents with
clinically suspected PID who were admitted to the
gynecology service through the emergency room at
the Medical College of Virginia. Each patient’s age,
race, gravidity and parity, and history of sexually
transmitted diseases were recorded at the time of
admission. All patients had CA125 levels drawn
and underwent laparoscopy at the time of admis-
sion.
Criteria for the clinical diagnosis of PID were
pelvic pain, the presence of bilateral adnexal ten-
derness during bimanual pelvic examination, and
the presence of leukorrhea by microscopy of the
vaginal secretions. Patients who were entered into
the study were clinically graded as to severity of
illness at the time of admission. Patients were con-
sidered to have clinically severe PID if they pre-
sented with a temperature >101 OF and/or a white
blood cell count >15,000/mL; otherwise, they were
clinically graded as mild.
Levels of CA125 antigen were determined with
an assay kit supplied by Centocor according to the
manufacturer’s instructions. Total assay time is ap-
proximately 26 hours.
Each patient admitted to the study underwent
laparoscopic diagnosis and, if found, grading of sal-
pingitis. Minimal criteria for the laparoscopic con-
firmation of acute salpingitis included tubal erythe-
ma, tubal edema, and purulent exudate either on
the tube, from the ostia, or in the cul de sac. Se-
verity of disease was graded according to the crite-
TABLE I. Demographic variables
Variable
Acute
salpingitis
(N 8)
Control
(normal tubes)
(N 6) P value
Age (years) 24.2 + 6.9 24.2 + 3.3 NS
Race 0.009
Black 24 2
White 4 3
Other 0
Gravidity 2.1 + 1.7 1.2_+ 1.6 NS
Parity 1.0 + I. 0.5 + 0.8 NS
History of GC 18 0.07
History of PID 6 2 NS
aNS, not significant.
bGC, gonorrhea.
cPID, pelvic inflammatory disease.
ria of Westrom and Mardh.8 Mild salpingitis was
therefore defined as meeting the above minimum
criteria with freely mobile tubes and patent ostia
(grade 1). Moderate salpingitis was defined as
tubes with more pronounced inflammation, fibrin-
ous exudates on the serosal surfaces, and tubes
which are not freely mobile (grade 2). Severe sal-
pingitis was defined by the presence of tuboovarian
abscess or adherence of pelvic organs to one an-
other (grade 3).
STATISTICAL ANALYSIS
Categorical variables were analyzed using the chi-
square or Fisher exact test as appropriate. Continu-
ous variables were analyzed using the paired t-test.
All P values were calculated based on two-tailed
tests with P < 0.05 considered significant.
RESULTS
The demographics of the patient population stud-
ied are shown in Table 1. The mean age of the
study population was 24.2 years. Most patients en-
tered into the study were African American (26/34).
There was no statistically significant difference be-
tween the group of patients found to have normal
tubes and those with salpingitis with respect to age,
gravidity, parity, history of gonorrhea, or history of
PID.
Parameters significantly different between the
salpingitis and no salpingitis (control) group in-
cluded admission temperature, admission status,
and C-reactive protein levels. Mean white-blood
cell count and mean CA125 levels also varied be-
tween the two groups, but these values failed to
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TABLE 2. Clinical variables
Control
Acute (normal
Variable salpingitis tubes) P value
Temperature (F) 100.9 + 1.8 99.2 + 0.6 0.0009
White blood cell count
1000/m3) 13.7 + 6. 8.2 + 2.8 0.06
C-reactive protein (mg/dL) 8.5 + 7.7 1.0 + 0.0 0.008
CAI25 (units) 28.9 + 60.6 7.5 + 0.0 0.07
reach statistical significance when using the Stu-
dent t-test for continuous variables. (Table 2).
When using a chi-square test comparing the
group with CA125 levels >7.5 units and the group
with levels -<7.5 units, there was statistical signifi-
cance between the two groups (P 0.002) (Table
3). Of the 34 patients recruited into the study, 28
(82.3%) were found to have salpingitis at laparos-
copy. Of the 28 patients with salpingitis, 20 had
CA125 levels above 7.5 units, seven had levels
above 16 units, and four had levels above 35 units.
Of the six patients with no salpingitis at laparosco-
py, none had CA125 levels above 7.5 units. All
women with CA125 levels above 16 units had vi-
sually graded severe (grade 3) salpingitis by lapa-
roscopy. CA125 levels increased with an increas-
ingly severe grade of salpingitis (Table 4).
Using 7.5 units as the cutoff for a normal CA125
level, the sensitivity of an abnormal level predict-
ing acute salpingitis in this population was 71%.
The specificity of a CA125 level >7.5 units was
100%. CA125 was not elevated in eight patients
with laparoscopic salpingitis. Predictive negative
value was therefore only 43%.
The pretest probability of a patient in this select
population having salpingitis was 0.82. The likeli-
hood ratio of patients with CA125 levels >7.5 units
having salpingitis compared with no salpingitis is
20/28:0/28.9 This cannot be calculated since the
denominator becomes zero. However, if we con-
sider a single patient with CA125 >7.5 units with-
out PID, as may occur with a larger study popula-
tion, the likelihood ratio becomes 20/28:1/28 or 20.
Using Fagan’s nomogram, the posttest probability
ofPID is >95% when a patient meeting the clinical
criteria for PID also has a CA125 level of >7.5. In
other words, the predictive value of the clinical
diagnosis alone versus the clinical diagnosis plus a
CA125 >7.5 units improved from 82% to more than
95% in diagnosing acute salpingitis.
TABLE 3. CAI25 as a predictor of salpingitis
at laparoscopy
Patients with Patients without
salpingitis salpingitis
CAI25 -< 7.5 units 8 6
CAI25 > 7.5 units 20 0
TABLE 4. Correlation of grade of salpingitis with
CA125 level
Grad& CA125 level (units)
0 7.5 +0.0
8.6_+3.1
2 11.0_+4.2
3 65. _+ 93.4
aGrade vs. 3, P 0.09; grade 0 vs. 3, P 0.08; grade 0 vs. 2, P not
significant.
DISCUSSION
Pelvic inflammatory disease is estimated to affect
approximately 1 million women a year for a total
annual cost of $3.5 billion. It is a cause of signifi-
cant morbidity in the female population. Salpingi-
tis increases the risk of ectopic pregnancy by six- to
tenfold, increases the risk for chronic pelvic pain,
causes infertility in 11% of women with their first
infection, and increases the risk of future PID,
leading to even higher levels of infertility with each
subsequent infection. PID tends to be readily
treatable with antibiotics when properly diagnosed;
therefore, the key to decreasing the morbidity from
this disease is in the diagnosis.
Unfortunately, salpingitis is not easily diagnosed
by clinical exam, routine laboratory tests, or nonin-
vasive imaging studies. The gold standard for the
diagnosis of salpingitis is laparoscopy, but it is not
practical to operate on every patient for whom the
diagnosis of PID is considered. A test that would
increase the likelihood of a particular subset of pa-
tients as having PID, and that would be able to
exclude those unlikely to have an upper genital
tract infection, would be extremely valuable for the
management of this illness. CA125 levels have
been proposed for use as a laboratory marker for
salpingitis.
In the group of patients studied, 7.5 units seems
to be the most logical CA125 level to use as a cutoff
for a normal CA125 level. Bast et al. noted in their
initial article that "the choice of limits for normal
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values is arbitrary. ’’1 Thirty-five units and 65 units
were chosen as potential cutoff values for norreal
when looking for ovarian cancer because only 1%
and 0.2%, respectively, of their normal population
had levels above these values. Since that test was
being evaluated for its utility in screening for ovar-
ian cancer in the population as a whole, a high
cutoff value for normal was chosen to increase the
specificity of the test. The investigators needed
high specificity because of the low incidence of the
targeted disease (ovarian cancer) within the general
population. Other authors have chosen 16 units or
30 units as their cutoff level when looking at
CA125 and salpingitis in select groups of pa-
tients,s,6
Only 3 patients (10.7%) in this study with acute
salpingitis by laparoscopy had a level of CA125
greater than 35 units. No patients with a CA125
level over 7.5 units had normal tubes at laparosco-
py. A higher cutoff level, at least in this particular
population, lowers the sensitivity of the test with-
out improving specificity, since one does not weed
out any false positives and only adds false nega-
tives. In this population, 7.5 units makes the most
sense as a cutoff value to optimize the utility of the
test.
The main limitation of this study is that the
population tested is not the actual population one
would like to have screened. In an emergency
room or office situation, the population in which a
diagnostic test would be helpful is that population
presenting with more atypical signs of PID. Pa-
tients with abdominal pain but no mucopus, mu-
copus but no cervical motion tenderness, or irregu-
lar bleeding of unclear etiology would all be popu-
lations for whom a diagnostic test to detect the
presence of salpingitis would be of value. Such a
patient population would clearly have a lower inci-
dence of PID and therefore challenge further the
ability of CA125 to diagnose patients with true sal-
pingitis. In this study’s high-incidence population,
CA125 appears to be correlated with the presence
of salpingitis, but these are women for whom the
clinical decision to admit and treat has already been
made. One might expect CA125 to perform less
well in a population with a lower incidence of dis-
ease.
As well as appearing only modestly helpful in
improving the clinical diagnosis of PID in predict-
ing salpingitis, the test for CA125 also poses a prac-
tical problem that would need to be addressed be-
fore it could be used clinically. Currently, the labo-
ratory technique requires a 24-hour incubation
period, precluding the rapid availability of results
needed in an office or emergency room setting.
This study suggests that serum CA125 determi-
nations modestly improve the predictive value of
the clinical diagnosis of PID to accurately reflect
the presence of acute salpingitis. Because the pre-
dictive negative value of the test appears to be low,
however, it does not seem that CA125 levels could
be used to rule out salpingitis. CA125 might be
useful to investigators looking for a way to rule in
salpingitis without laparoscopy in a study popula-
tion.
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